# Shorts on Fire: November's Must-Watch Picks! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-11-17T13:00:04.890Z Source: https://newsyai.com/edition/e9993746-82ed-4ac5-8caf-4eef94d749a5 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Wall Street's Short Sizzle: Fresh November 17, 2026 Edition – "These Shorts Are Begging for a Spanking"** Back at it, you beautiful degenerates. Markets remain the same glorious shitshow—AI hype juicing the Nasdaq while the Dow sits on its ass like a retiree in Boca, and crude oil bounces around like a drunk on a pogo stick. I scoured the freshest short-interest scans and signals (including live borrow vibes and volatility overlays from recent settlement data) for three *brand-new* names where the bears are piled higher than a Wall Street bonus pool on a bad year, and the bulls are yelling “squeeze me harder.” No repeats of the usual suspects like CSIQ, BYND, CRK, or the prior crypto/AI/biotech/nuclear/solar crew. Just pure, unfiltered fresh meat with serious short pressure and “prove me wrong, bitch” vibes. Here’s today’s unholy trinity.[[1]](https://tapeboard.com/most-shorted-stocks)[[1]](https://tapeboard.com/most-shorted-stocks) ### 1. SPCE (Virgin Galactic): The Space Tourism Playboy That's Either Blasting Off to the Stars or Crashing Back to Earth in a Fiery Reentry of Delays and Cash Burns **The Bull Case (Virgin Brand Hype, Tourism Boom, and Squeeze Juice):** Bulls are creaming over SPCE’s first-mover edge in commercial spaceflight—pent-up demand for suborbital joyrides, Branson’s celebrity cachet, and any successful flight cadence or sector rotation could trigger a short squeeze (recent scans flagging ~25-40% of float short with solid days-to-cover). “We’ve got the brand, the vision, and the asymmetric upside—watch the shorts get SPCE’d when tickets sell like hotcakes” is the battle cry.[[2]](https://curvedtrading.com/stocks/spce/) **The Bear Case (Chronic Delays, Cash Incineration, and Classic Space Startup Inferno):** Reality check: Brutal questions on repeated timeline slips, massive cash burn with limited runway, dilution risks from ongoing raises, regulatory hurdles, and competition from better-funded players. High short pressure reflects the market’s “yeah, right” on flawless execution in a capital-intensive, hype-driven niche. One more delay, funding crunch, or earnings blowup and it’s pain. Virgin Galactic? More like “Virgin Galac-tic—shorts are harvesting the downside.” **My First-Principles Breakdown:** Strip it down: Space tourism winners need reliable flight cadence, defensible tech/IP, resilient balance sheets across cycles, and actual revenue—not just “space is cool” buzz. SPCE has real brand equity and early mover status, but “success” requires proving repeatable operations without endless dilution or setbacks. Shorts correctly price in the execution and burn risks; bulls correctly price in the demand asymmetry if flights stick. High-vol speculative bet—entertaining as hell, size accordingly or cry into your empty spacesuit later. ### 2. TNGX (Tango Therapeutics): The Precision Oncology Upstart That's Either Curing Cancer or Getting Slaughtered by Trial Failures and Biotech Burn **The Bull Case (Pipeline Promise, Data Catalysts, and Squeeze Fuel):** Bulls are pumped on TNGX’s targeted protein degradation and oncology platform—promising early data readouts, potential partnerships, and any positive ESMO or clinical news could spark a short squeeze (recent data flagging ~30-40% of float short with elevated days-to-cover). “We’ve got the science, the targets, and the hype—watch the shorts get TNGX’d when trials deliver” is the mantra.[[3]](https://www.mboum.com/quotes/TNGX?v=short_interest) **The Bear Case (Clinical Risks, Cash Burn Inferno, and Classic Biotech Skepticism):** Reality bites: Brutal risks from binary trial outcomes, high R&D spend with ongoing losses, competition in crowded oncology space, and dilution or funding concerns. High short pressure reflects the market’s “yeah, right” on flawless navigation of regulatory and efficacy hurdles. One missed endpoint, safety issue, or capital raise and it’s pain. Tango Therapeutics? More like “Tango with Disaster—shorts are harvesting the downside.” **My First-Principles Breakdown:** Fundamentally, biotech winners win on differentiated science, de-risked pipelines, resilient economics across development cycles, and eventual profitability—not just “precision medicine” buzz. TNGX has real platform potential and data momentum, but “breakout” requires surviving clinical binary events, proving commercial viability without endless raises, and navigating fierce competition. Shorts correctly flag the trial and burn risks; bulls correctly flag the disruption upside if data sticks. High-vol biotech bet—entertaining as hell, size accordingly or cry into your empty lab notebook later. ### 3. TE (T1 Energy Inc.): The Solar Module Maker That's Either Powering the Domestic Grid or Getting Fried by Oversupply, Tariffs, and Dilution Drama **The Bull Case (U.S. Manufacturing Tailwinds, Of take Deals, and Squeeze Juice):** Bulls are fired up on TE’s domestic solar push—IRA incentives, new multi-GW offtake agreements, polysilicon waivers, and any policy or sector rotation could spark a short squeeze (recent scans showing ~30-40% of float short with decent days-to-cover). “We’ve got the U.S. footprint, the contracts, and the asymmetric upside—watch the shorts get TE’d when panels fly” is the hype.[[4]](https://www.marketbeat.com/stocks/NYSE/TE/short-interest/) **The Bear Case (Global Oversupply Hell, Customer Concentration, and Classic Execution Inferno):** Reality check: Brutal questions on intense Chinese competition and pricing pressure, heavy reliance on a single major customer, ongoing losses and cash burn, dilution risks from share authorization, and policy/geopolitical whiplash. High short pressure reflects the market’s “yeah, right” on flawless navigation of oversupply and funding gaps. One tariff shift, demand miss, or earnings blowup and it’s pain. T1 Energy? More like “T1 Agony—shorts are harvesting the downside.” **My First-Principles Breakdown:** Solar/renewables winners need resilient supply chains, diversified customers, pricing power across cycles, and actual free cash flow—not just “green wave” or “domestic content” buzz. TE has real manufacturing scale and policy tailwinds, but “success” requires surviving commodity cycles, proving execution without endless dilution, and avoiding concentration traps. Shorts correctly price in the cyclical and operational risks; bulls correctly price in the demand asymmetry if the reset sticks. High-vol energy bet—entertaining as hell, size accordingly or cry into your empty module warehouse later. **Bottom Line (No Crystal Ball, Just Brutal Logic):** These three capture the current divided vibe: space tourism binary, biotech clinical gamble, and solar policy/execution tightrope. The common thread? Sky-high skepticism via short signals and volatility, but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don’t), and remember: this is entertainment with numbers. Your move, degenerates. **Sources for the terminally curious (verify this shit yourself):** Recent short-interest trackers and signals (e.g., Tapeboard, ChartMill, MarketBeat, ORTEX, CurvedTrading) highlighting elevated pressure in SPCE, TNGX, and TE; company updates, sector debates, and filings on space, biotech, and solar/energy. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don’t cry when it goes tits up.